Cinclus Pharma: All patients have completed treatment in Phase III study - Redeye
Redeye briefly comments on Cinclus Pharma’s announcement that the last patient in the phase III HEEALING1 study with lead candidate linaprazan glurate has completed the full eight-week treatment period.
ANNONS
Redeye briefly comments on Cinclus Pharma’s announcement that the last patient in the phase III HEEALING1 study with lead candidate linaprazan glurate has completed the full eight-week treatment period.
